| 1) icantly attenuated in GGT-knockdown A549 cells. |
| 2) quired for immature versus mature CD4+ T cells. |
| 3) lso be applied for immature human CD4+ T cells. |
| 4) ing DNA repair capacity in living primary cells. |
| 5) ulatory T cells, and regulatory dendritic cells. |
| 6) directly insults the CNS barrier-forming cells. |
| 7) rimary acute lymphoblastic leukemia (ALL) cells. |
| 8) stable (MSS) and MSI-H colorectal cancer cells. |
| 9) y pathway for the differentiation of NKT2 cells. |
| 10) ith GD3 chimeric antigen receptor (CAR) T cells. |
| 11) nes are often used to study innate-like T cells. |
| 12) upregulated genes in more advanced tumor cells. |
| 13) to inhibit phagocytosis by innate immune cells. |
| 14) the mechanism of entry of SARS-CoV-2 into cells. |
| 15) n the cell viability of gastric carcinoma cells. |
| 16) ITGB1 levels and limited mobility of HCC cells. |
| 17) adation and promoted dissemination of HCC cells. |
| 18) er expression of hair follicle progenitor cells. |
| 19) enhanced the expression of LBX2-AS1 in OC cells. |
| 20) of bona fide off-target cleavage sites in cells. |
| 21) protein mNeonGreen and visualized in live cells. |
| 22) n activation, entry, and spread into host cells. |
| 23) hly correlated activity across chandelier cells. |
| 24) x43) and Cx30, which form plaques between cells. |
| 25) tegrin beta 1 (ITGB1) for motility of HCC cells. |
| 26) at telomeres or mitochondria in Jurkat T cells. |
| 27) ses gene transcripts specific to ciliated cells. |
| 28) term effects of drug treatment on BCP-ALL cells. |
| 29) to form cardiac and branchiomeric muscle cells. |
| 30) ntribute to the higher Ca2+ level in NKT2 cells. |
| 31) gainst toxicity was partially lost in SNP cells. |
| 32) s elicited significant apoptosis of DLBCL cells. |
| 33) ntation of MMP12 in the liver and Kupffer cells. |
| |